Record-breaking quarter driven by robust performance in the Dermo-cosmetics division.
Plexuspharmaco reported exceptional Q2 financial results, with European revenue growing by 24% year-over-year. The strong performance was spearheaded by our newly launched Dermo-cosmetics line and expanded cardiovascular portfolio. [PENDING CLIENT APPROVAL]